Iteos Therapeutics Company Insiders
| ITOS Stock | USD 8.00 0.26 3.36% |
Iteos Therapeutics employs about 157 people. The company is managed by 11 executives with a total tenure of roughly 367 years, averaging almost 33.0 years of service per executive, having 14.27 employees per reported executive. Breaking down Iteos Therapeutics' management performance can provide insight into the firm performance.
Iteos |
Iteos Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.1304) % which means that it has lost $0.1304 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1972) %, meaning that it created substantial loss on money invested by shareholders. Iteos Therapeutics' management efficiency ratios could be used to measure how well Iteos Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.16 in 2025. Return On Capital Employed is likely to drop to -0.23 in 2025. At this time, Iteos Therapeutics' Net Tangible Assets are comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 141.2 M in 2025, whereas Non Currrent Assets Other are likely to drop slightly above 3.5 M in 2025.Net Income Applicable To Common Shares is likely to gain to about 116.7 M in 2025, whereas Common Stock Shares Outstanding is likely to drop slightly above 34.6 M in 2025.
Iteos Therapeutics Workforce Comparison
Iteos Therapeutics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 4,805. Iteos Therapeutics holds roughly 157 in number of employees claiming about 3% of equities under Health Care industry.
Iteos Therapeutics Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Iteos Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Iteos Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Iteos Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-09-01 | 2.0 | 2 | 1 | 792,800 | 442,800 |
| 2024-06-01 | 11.0 | 11 | 1 | 7,950,742 | 900,000 |
| 2023-03-01 | 3.5 | 7 | 2 | 1,161,223 | 295,223 |
| 2022-06-01 | 1.0455 | 23 | 22 | 609,674 | 1,390,503 |
| 2022-03-01 | 0.2857 | 14 | 49 | 770,000 | 2,476,063 |
| 2021-12-01 | 0.0993 | 15 | 151 | 1,583,134 | 3,227,891 |
| 2021-09-01 | 0.0119 | 1 | 84 | 53,672 | 1,468,720 |
| 2021-06-01 | 0.6216 | 23 | 37 | 777,651 | 247,872 |
| 2020-09-01 | 2.9286 | 82 | 28 | 27,995,259 | 19,529,220 |
Iteos Therapeutics Notable Stakeholders
An Iteos Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Iteos Therapeutics often face trade-offs trying to please all of them. Iteos Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Iteos Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Michel Detheux | CEO President | Profile | |
| Phillipe Brantegem | VicePresident Resources | Profile | |
| Matthew Gall | Chief Officer | Profile | |
| Matthew MBA | Chief Officer | Profile | |
| Ryan Baker | Head Relations | Profile | |
| Joanne MD | Chief Officer | Profile | |
| Adi Osovsky | Executive Legal | Profile | |
| Yvonne McGrath | Chief Officer | Profile | |
| FACP MD | Interim Officer | Profile | |
| David MD | Chief Officer | Profile | |
| Philippe Brantegem | Executive Resources | Profile |
About Iteos Therapeutics Management Performance
The success or failure of an entity such as Iteos Therapeutics often depends on how effective the management is. Iteos Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Iteos management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Iteos management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.15) | (0.16) | |
| Return On Capital Employed | (0.22) | (0.23) | |
| Return On Assets | (0.15) | (0.16) | |
| Return On Equity | (0.18) | (0.19) |
Please note, the imprecision that can be found in Iteos Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Iteos Therapeutics. Check Iteos Therapeutics' Beneish M Score to see the likelihood of Iteos Therapeutics' management manipulating its earnings.
Iteos Therapeutics Workforce Analysis
Traditionally, organizations such as Iteos Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Iteos Therapeutics within its industry.Iteos Therapeutics Manpower Efficiency
Return on Iteos Therapeutics Manpower
| Revenue Per Employee | 80.2K | |
| Revenue Per Executive | 1.1M | |
| Net Loss Per Employee | 717.5K | |
| Net Loss Per Executive | 10.2M | |
| Working Capital Per Employee | 3.3M | |
| Working Capital Per Executive | 46.4M |
Additional Tools for Iteos Stock Analysis
When running Iteos Therapeutics' price analysis, check to measure Iteos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Iteos Therapeutics is operating at the current time. Most of Iteos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Iteos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Iteos Therapeutics' price. Additionally, you may evaluate how the addition of Iteos Therapeutics to your portfolios can decrease your overall portfolio volatility.